MN Pharmaceuticals is one of the leading and oldest pharmaceutical companies in Turkey. The company was established in 1923 in a district of Ýstanbul known as Üsküdar, Ýhsaniye under the name of Mustafa Nevzat Laboratory. With its 8 employees, the 'Laboratory' was one of the first manufacturers of injectable products in Turkey.
Its founder Prof. Mustafa Nevzat Pýsak played an important role in establishing contemporary pharmacy in Turkey, in changing the academic pharmacy program to one fashioned on Western methods, and in the development of the Turkish Pharmaceutical Industry.
Mustafa Nevzat Pýsak was born in Gonen in 1879. He graduated from the Military Medical School in 1898 as a pharmacist candidate and from the Imperial Faculty of Medicine in 1902 as a pharmacist-chemist. His first job was in the Selanik Military Hospital in Macedonia. He came to Istanbul in 1909 with the Action Army. In 1911 he was appointed as the laboratory chief of the Medical School and in 1915 as the professor of pharmaceutical technology in the School of Pharmacy. He also taught Materia Medica at the Faculty of Medicine.
The 'Laboratory' moved to another district, Divanyolu, and then to Nuruosmaniye in 1933. In 1957 it moved to Mecidiyeköy and became a joint stock company. In 1984, in addition to the plant in Mecidiyeköy, the Yenibosna facilities were established. The plant in Mecidiyeköy, in turn, has moved to its present location at Yenibosna in 2003.
Currently, with its trained personnel of 1060 and modern facilities, MN Pharmaceuticals is one of the leading manufacturers of active pharmaceutical ingredients and finished dosage forms in Turkey.
There are four separate production units of the Active Pharmaceutical Ingredients Plant; penicillin group active substances, macrolide group active substances and etodolac, and other active substances are manufactured. In Production Plant I, penicillin group antibiotics like Sulbactam Sodium, Sultamicillin Tosylate and Sultamicillin Base are manufactured. In Production Plant II, Etodolac, Voriconazole and macrolide group antibiotics like Clarithromycin granules are manufactured. In Production Plant III and Plant IV productions of 1-500 kg capacities take place; in this Pilot and Small Scale Production Plants, active substances like Granisetron, Zoledronic Acid, Rocuronium Bromide, Aripiprazole, Monosodium Ibandronate Monohydrate and Imatinib Mesylate are manufactured.
There are four dedicated production plants for finished dosage forms in Yenibosna, Ýstanbul; all basic forms of pharmaceuticals, including injectables such as liquid and freeze-dried ampoules and vials, sterile powder vials and oral dosage forms such as hard gelatin capsules, tablets, film-coated tablets and dry powder suspensions are produced in Yenibosna.
With its high-capacity injectable units and lyophilization facilities, MN Pharmaceuticals is Turkey's most experienced pharmaceutical company in parenteral drug manufacturing.
Penicillin-like and cephalosporin-like beta-lactam products are produced in two separate, dedicated plants.
In a separate and dedicated third plant, other groups of antibiotics, corticosteroids, cardiovascular agents, anti-inflammatory agents, gastrointestinal agents and agents belonging to other therapeutic groups are manufactured.
The newly established and the fourth finished dosage forms plant, Injectable Oncology Products Plant has been completed at the beginning of 2009. In this plant, dosage forms in liquid and freeze-dried vials are manufactured.
The products are manufactured according to 'Current Good Manufacturing Practices (cGMP)' and 'Current Good Laboratory Practices (cGLP)' and as a result of continuous training, education and modern technology; the products are used by patients both in Turkey and in various countries abroad
In July 2004, MN Pharmaceuticals received EU-GMP certificate from Germany for the ampicillin sodium / sulbactam sodium for injection. This certificate has been renewed following the inspections in 2007 and 2009.
MN Pharmaceuticals signed strategic partnership agreements with several leading US generic companies for marketing and sales of its products and has submitted the first ANDA dossier to FDA in 2005. This is also a 'first' for the Turkish Pharmaceutical Industry. By taking the initial step in exporting finished dosage forms to the US, MN Pharmaceuticals has paved the way for the other Turkish pharmaceutical companies to follow.
In November 2006, our API and finished dosage forms facilities have been inspected by FDA. As a result of FDA inspection, MN Pharmaceuticals has been the first Turkish Pharma Company which has been granted the FDA approval for the API and finished dosage forms.
The finished dosage forms facilities have been awarded the Environment Management System Certificate in the scope of ISO 14001 Standards by the British Management Systems Organization BSI in 2007. In May 2007, the first export of finished dosage forms was performed from Turkey to the USA. In July 2008, the second product entered the US market.
As a result of MHRA inspection conducted in May 2008, MN Pharmaceuticals received the Certificate of GMP Compliance of a Manufacturer from the British Ministry of Health.
In January 2009, following the certification investigation studies conducted by Turkish Standards Institute, MN Pharmaceuticals Active Pharmaceutical Ingredients Plant has been awarded the Environment Management System Certificate in the scope of TSE ISO 14001 Standards. The finished dosage forms facilities have been awarded the OHSAS 18001 Occupational Health and Safety Certificate which was presented by the British Management Systems Organization BSI.
In January 2010, the third product was launched in the U.S.A.
The Oncolytic Products Plant was approved by the US Food and Drug Administration (FDA) in May 2010 and by the European Medicine Agency (EMEA) in July 2010.
In December 2010, the oncolytic drugs were shipped from Turkey to USA for the first time.
Prof. Mustafa Nevzat Pýsak's professional aim of always accomplishing the best and his great respect for human welfare are still the basic principles of MN Pharmaceuticals.